Several inhibitors of IL-1, including the IL-1β blocking antibody canakinumab, the IL-1 trapping fusion protein rilonacept, and the recombinant IL-1R antagonist anakinra, have been approved for the treatment of multiple inflammatory and autoimmune diseases, such as RA [468], cryopyrin-associated periodic syndrome (CAPS) [469, 470], and children and adult Still’s disease [471]. This evidence concerns the gene IL1A and cryopyrin-associated periodic syndrome.